The growth in profit was led by superior brand-building activities and supported by strengthened supply chain and go-to-market capabilities, P&G Health said in a statement.

The Mumbai-based company's revenue from operations increased 19% on a year-on-year (YoY) basis to ₹370 crore in the January to March quarter as against ₹311 crore seen in Q4 FY25.

Its operating profit, also known as earnings before interest, taxes, depreciation, and amortisation (EBITDA), surged 67% to ₹135 crore as against ₹81 crore in the corresponding period last year.

Its EBITDA margin expanded to 36.57% in contrast to 26.02% in the year-ago period.

During the quarter, the company delivered sales of ₹365 crore, up 20% compared to last year, driven by strong brand fundamentals and positive consumer response to new innovations.

P&G Health said it closed the 12-month financial year with reported sales of ₹1,385 crore and a profit after tax of ₹327 crore, reflecting growth of 16% and 30%, respectively, compared with the corresponding 12-month period from April 2024 to March 2025.

The board of directors of P&G Health also recommended a dividend of ₹45 per equity share (face value of ₹10 each) for the financial year ended March 31, 2026. The proposal is subject to approval by shareholders at the ensuing Annual General Meeting (AGM).

The company added that, if approved, the dividend will be paid on or before September 25, 2026.

"We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities," said Milind Thatte, Managing Director, Procter & Gamble Health.

Furthermore, P&G Health said its business continues to grow on the back of a strong pipeline of product innovations with a consumer-centric approach. The company highlighted launches such as Livogen Iron Gummies, an easy-to-consume format for iron supplementation, and Neurobion Nerve Pain Relief Cream, a topical solution aimed at providing symptomatic relief from nerve-related pain.

It added that during the year, it continued to drive community impact through its corporate social responsibility initiative, P&G Sehat, which focuses on improving healthcare access and awareness in underserved communities across the country. The initiative has impacted over 15 lakh lives since its inception.

On Tuesday, shares of P&G Health closed at ₹5,652.50 apiece on the National Stock Exchange, falling 1.28%.